BrainsWay Reports Strong Q2 Earnings Growth Amid Strategic Expansion
BrainsWay (BWAY) reported strong financial results for the second quarter of 2026, with revenue reaching $17.1 million—a 35% increase from the prior year period. The company shipped 125 Deep TMS systems during the quarter, a 42% rise compared to Q2 2025, and now has an installed base of approximately 1,950 units. Operating income surged by over 300%, reaching $2.4 million, while adjusted EBITDA rose 141% to $3.5 million with a margin expansion from 11% to 20%. The company also raised its full-year revenue guidance to between $68 million and $70 million. Management highlighted the adoption of the SWIFT accelerated treatment protocol as a key growth driver, which has enabled clinics to treat more patients efficiently. BrainsWay is transitioning from being primarily a Deep TMS device manufacturer into an interventional psychiatry platform through strategic investments in behavioral health provider clinics like HopeMark Health and Radial Health. The company remains profitable for 12 consecutive quarters with $62.4 million in cash reserves as of June 30, 2026. The firm also noted a significant international market opportunity, estimating over 170 million untreated patients across current partner markets.
Tickers: $BWAY
Topics: ebitda financial_performance operating_income revenue